Mesoblast - adult stem cell technology, regeneration of adult stem cells, repair and regrowth of bone and cartilage Melbourne, Australia

****JavaScript based drop down DHTML menu generated by Visual QuickMenu Pro. (OpenCube Inc. - http://www.opencube.com)****

The vision for Mesoblast – to become the world leader in novel therapeutic approaches for patients with bone and joint diseases, including adult stem cell therapy for bone fractures and spinal disease, and for regeneration of damaged joint cartilage and intervertebral discs.

unique adult stem cell technology for orthopaedic applications for patients with bone and cartilage degeneration. Repair and regrowth of adult stem cells, Melbourne Australia

Mesoblast - the regenerative medicine company

Mesoblast Limited (ACN 109 431 870) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the commercialisation of unique adult stem cells to regenerate and repair bone and cartilage.

Mesoblast - The adult stem cell company. The vision for Mesoblast – to become the world leader in adult stem cell therapy for patients with bone and cartilage degeneration

Mesoblast Limited (ASX:MSB; USOTC:MBLTY), which listed on the Australian Stock Exchange in December 2004, has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The technology has achieved outstanding results in clinical and preclinical trials in the regeneration and repair of large bone fractures and cartilage.

The Company has also acquired a substantial equity holding in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology.

Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones .